Heidi S. Rønde

Dr. Heidi S. Rønde

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
AAAne Appelt
Ane Appelt
PAPiotr Andrzejewski
Piotr Andrzejewski
LHLone Hoffmann
Lone Hoffmann
CKColin Kelly
Colin Kelly
CMChrysanthi Michailidou
Chrysanthi Michailidou
MPMarija Popovic
Marija Popovic
Reirradiation is increasingly used, but its safe application requires accurate evaluation of cumulative doses to organs at risk. Methods of cumulative dose evaluation vary widely, from simple summation of prescription doses to complex three-dimensional (3D) dose summation methodologies, yet best practices remain undefined. This guidance, endorsed by the ESTRO Reirradiation Focus Group, provides detailed recommendations on the technical aspects of 3D dose summation; appropriate alternatives when it is unfeasible, suboptimal, or requires special considerations; and general guidance on uncertainty evaluation, resource management, and implications for treatment delivery. The writing group (n = 15) analysed scenarios ranging from full 3D dose summation to situations with incomplete data and unacceptable image registration, and developed recommendations through structured expert discussion and a two-step voting process. Key discussion points included: dose mapping (with rigid and deformable image registration), radiobiological corrections (particularly equieffective dose rescaling, such as EQD2Gy and BED), uncertainties, role of documentation, quality control, and peer review. Thirty-five statements reached consensus within both the writing group and the full ESTRO Physics Reirradiation Working Group (n = 34, 66 % response rate). Altogether, this guidance offers a practical framework for standardizing the technical aspects of cumulative dose evaluation to support clinical decision making and improve safety and effectiveness of reirradiation, while reducing institutional variability. It also highlights ongoing needs for research into advanced dose mapping, image registration, and integration of uncertainty analyses.

10 November 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JWJonas Willmann
Jonas Willmann
PBPanagiotis Balermpas
Panagiotis Balermpas
ARAndreas Rimner
Andreas Rimner
AAAne L Appelt
Ane L Appelt
EOEliana Maria Vasquez Osorio
Eliana Maria Vasquez Osorio
NANicolaus Andratschke
Nicolaus Andratschke
Reirradiation has gained increasing interest, as advances in systemic therapy increase the survival of patients with cancer, and modern radiation techniques allow more precise treatments. However, high-quality prospective evidence on the safety and efficacy of reirradiation to guide clinical practice remains scarce. This systematic review evaluates ongoing prospective studies on reirradiation to identify research gaps and priorities. A systematic review of ClinicalTrials.gov was conducted on July 11, 2024, using search terms related to reirradiation. Inclusion criteria were prospective studies that were "recruiting," "not yet recruiting," or "active, not recruiting." Studies with published results, retrospective, and in-silico studies were excluded. The review followed PRISMA 2020 guidelines and recommendations for systematic searches of clinical trial registries. Among 1026 identified studies, 307 were screened, 99 were included. Fourty (40%) focused on central nervous system (CNS), 23 (23%) head and neck, and 17 (17%) on pelvic reirradiation. Most studies (90%) were interventional, with 32 (32%) phase II and 4 (4%) phase III trials. Sixteen trials were randomized (RCTs), including the 4 phase III trials for recurrent glioblastoma, rectal and nasopharyngeal cancer. Ten dose escalation trials focus on recurrent prostate, rectal, and non-small cell lung cancer as well as glioma. Modern high-precision radiotherapy techniques were frequently used, with 21 (21%) studies using stereotactic radiotherapy and 17 (17%) using particle therapy. Combinations with systemic therapies were investigated in 41 (41%) studies. Ongoing studies most frequently focus on CNS, head and neck, and pelvic reirradiation. There remains a critical need for RCTs, in particular for lung, breast, and gynecological cancers. Dose escalation trials, application of precision radiation techniques and combinations with modern systemic therapy may help define the optimal multimodality treatment schedules.

8 September 2023 in Acta Oncologica
Verified
Journal Article
Closed access
HRHeidi S. Rønde
Heidi S. Rønde
CKCamilla Kronborg
Camilla Kronborg
MHMorten Høyer
Morten Høyer
JHJolanta Hansen
Jolanta Hansen
MBMalene Eppler Bak
Malene Eppler Bak
JKJesper F. Kallehauge
Jesper F. Kallehauge
Patients with stage II seminoma have traditionally been treated with photons to the retroperitoneal and iliac space, which leads to a substantial dose bath to abdominal and pelvic organs at risk (OAR). As these patients are young and with excellent prognosis, reducing dose to OAR and thereby the risk of secondary cancer is of utmost importance. We compared IMPT to opposing IMRT fields and VMAT, assessing dose to OAR and both overall and organ-specific secondary cancer risk. A comparative treatment planning study was conducted on planning CT-scans from ten patients with stage II seminoma, treated with photons to a 'dog-leg' field with doses ranging from 20 to 25 Gy and a 10 Gy sequential boost to the metastatic lymph node(s). Photon plans were either 3-4 field IMRT (Eclipse) or 1-2 arc VMAT (Pinnacle). Proton plans used robust (5 mm; 3.5%) IMPT (Eclipse), multi field optimization with 3 posterior fields supplemented by 2 anterior fields at the level of the iliac vessels. Thirty plans were generated. Mean doses to OARs were compared for IMRT vs IMPT and VMAT vs IMPT. The risk of secondary cancer was calculated according to the model described by Schneider, using excess absolute risk (EAR, per 10,000 persons per year) for body outline, stomach, duodenum, pancreas, bowel, bladder and spinal cord. Mean doses to all OARs were significantly lower with IMPT except similar kidney (IMRT) and spinal cord (VMAT) doses. The relative EAR for body outline was 0.59 for IMPT/IMRT (p < .05) and 0.33 for IMPT/VMAT (p < .05). Organ specific secondary cancer risk was also lower for IMPT except for pancreas and duodenum. Proton therapy reduced radiation dose to OAR compared to both IMRT and VMAT plans, and potentially reduce the risk of secondary cancer both overall and for most OAR.

15 July 2021 in Acta Oncologica
Verified
Journal Article
Closed access
HRHeidi S. Rønde
Heidi S. Rønde
JKJ. F. Kallehauge
J. F. Kallehauge
CKC. J. S. Kronborg
C. J. S. Kronborg
LNL. Nyvang
L. Nyvang
BRB. L. Rekstad
B. L. Rekstad
KSK. L. S Spindler
K. L. S Spindler
Advanced rectal cancers are treated with neo-adjuvant (chemo)radiotherapy followed by surgery, but 5–10% experience locoregional recurrence after initial treatment. Radical (R0) salvage surgery is ...

9 July 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
MNMorten Nielsen
Morten Nielsen
MLMai-Britt Linaa
Mai-Britt Linaa
VHVibeke Nordmark Hansen
Vibeke Nordmark Hansen
LKLaura Patricia Kaplan
Laura Patricia Kaplan
MLMikkel Drøgemüller Lund
Mikkel Drøgemüller Lund
AAAne Appelt
Ane Appelt
Background and purpose: Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing. As a precursor to a prospective national reirradiation registry, a comprehensive national audit of reirradiation was performed. Patients/materials and methods: Radiotherapy retreatment courses in 2023 were audited by all (eight) radiotherapy centres in Denmark. Six centres extended the evaluation to include 2021–22, and three of these also evaluated preceding years. Reirradiation was defined according to the ESTRO/EORTC consensus (i.e. treatment volume overlap or cumulative dose toxicity risk) using 3 months threshold between the primary and reirradiation courses. Reirradiation courses were further stratified into curative/ablative and palliative treatments by prescription dose. Results: The total number of radiotherapy patients at Danish centres in 2023 was 17,424. Of these, 3,163 received retreatment, including 1,471 reirradiation courses (1,035 palliative; 436 curative/ablative). From 2014 to 2023, absolute numbers for both retreatment and reirradiation increased. We found large variation in prescription doses and fractionation schedules used for reirradiation. Widely used palliative prescriptions were 8Gy/1 fraction (F), 20Gy/4F and 30Gy/10F; stereotactic prescriptions of 20Gy/1F or 27Gy/3F in brain and 45Gy/3F in lung; and a variety of curative treatments schedules. Palliative reirradiations were primarily thoracic (29%), spine (25%), and abdominal/pelvic (22%) and curative/ablative reirradiations were primarily breast (29%) and lung stereotactic (23%). Interpretation: This is the first comprehensive national audit of reirradiation, demonstrating an increasing number of patients being treated, using a wide variety of dose prescriptions and fractionation schedules.

27 April 2017 in Acta Oncologica
Verified
Journal Article
Open access
HRHeidi S. Rønde
Heidi S. Rønde
LWLeonard Wee
Leonard Wee
JPJohn Pløen
John Pløen
AAAne Appelt
Ane Appelt
Purpose/Objective: Chemo-radiotherapy is an established primary curative treatment for anal cancer, but clinically equal rationale for different target doses exists. If joint preferences (physician and patient) are used to determine acceptable tradeoffs in radiotherapy treatment planning, multiple dose plans must be simultaneously explored. We quantified the degree to which different toxicity priorities might be incorporated into treatment plan selection, to elucidate the feasible decision space for shared decision making in anal cancer radiotherapy. Material and methods: Retrospective plans were generated for 22 anal cancer patients. Multi-criteria optimization handles dynamically changing priorities between clinical objectives while meeting fixed clinical constraints. Four unique dose distributions were designed to represent a wide span of clinically relevant objectives: high-dose preference (60.2 Gy tumor boost and 50.4 Gy to elective nodes with physician-defined order of priorities), low-dose preference (53.75 Gy tumor boost, 45 Gy to elective nodes, physician-defined priorities), bowel sparing preference (lower dose levels and priority for bowel avoidance) and bladder sparing preference (lower dose levels and priority for bladder avoidance). Results: Plans satisfied constraints for target coverage. A senior oncologist approved a random subset of plans for quality assurance. Compared to a high-dose preference, bowel sparing was clinically meaningful at the lower prescribed dose [median change in V45Gy: 234 cm3; inter-quartile range (66; 247); p < .01] and for a bowel sparing preference [median change in V45Gy: 281 cm3; (73; 488); p < .01]. Compared to a high-dose preference, bladder sparing was clinically meaningful at the lower prescribed dose [median change in V35Gy: 13.7%-points; (0.3; 30.6); p < .01] and for a bladder sparing preference [median change in V35Gy: 30.3%-points; (12.4; 43.1); p < .01]. Conclusions: There is decision space available in anal cancer radiotherapy to incorporate preferences, although tradeoffs are highly patient-dependent. This study demonstrates that preference-informed dose planning is feasible for clinical studies utilizing shared decision making.